KISQALI® (ribociclib) for HR+, HER2- Metastatic Breast Cancer
WEBKISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with: an aromatase inhibitor as the first endocrine-based therapy; or...
eBC and mBC Treatment | KISQALI (ribociclib)
WEBKISQALI ® (ribociclib) is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer: in combination with an aromatase inhibitor for stage II and III early breast cancer with a high risk of coming back
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
WEB5 days ago · Ad hoc announcement pursuant to Art. 53 LR. Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1,2; Kisqali ® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile ...
Ribociclib plus Endocrine Therapy in Early Breast Cancer
WEBMar 20, 2024 · The NATALEE trial is a phase 3 trial comparing ribociclib plus endocrine therapy with endocrine therapy alone that was designed to test CDK4/6 inhibition in a broad population of patients with...
Kisqali: What to Expect, Side Effects, and More - Breastcancer.org
WEBKisqali (ribociclib) is a CDK4/6 inhibitor used to treat certain cases of estrogen-receptor-positive, HER2-negative breast cancer.
FDA approves ribociclib with an aromatase inhibitor and ribociclib …
WEB5 days ago · Efficacy of ribociclib with a non-steroidal aromatase inhibitor (NSAI) was evaluated in NATALEE (NCT03701334), a randomized, open-label, multicenter trial in 5101 adults with HR-positive, HER2 ...
How KISQALI® (ribociclib) Works
WEBLearn how KISQALI can work as a possible HR+, HER2- metastatic breast cancer treatment combined with hormone therapy. See full Prescribing & Safety Info.
FDA approves first cancer drug through new oncology review pilot …
WEBThe U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone...
Ribociclib Improves Survival in Advanced Breast Cancer
WEBOct 6, 2021 · Women with metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their initial treatment lived approximately 1 year longer overall than women treated with letrozole only, updated results from the MONALEESA-2 …
Novartis ribociclib (Kisqali®) only Category 1 preferred first-line ...
WEBMar 28, 2023 · KISQALI ® (ribociclib) is a prescription medicine used to treat adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with: an aromatase inhibitor …